Biogen (BIIB) Tops Q4 EPS by 38c, Beats on Revenue; Offers FY26 EPS Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
Tweet
Share
E-mail
Get Alerts BIIB Hot Sheet
Price: $240.98 -0.87%
EPS Growth %: -58.0%
Financial Fact:
Total cost and expenses: 1.53B
Today's EPS Names:
FNLC, LSBK, OVLY, More
EPS Growth %: -58.0%
Financial Fact:
Total cost and expenses: 1.53B
Today's EPS Names:
FNLC, LSBK, OVLY, More
Join SI Premium – FREE
Biogen (NASDAQ: BIIB) reported Q4 EPS of $1.99, $0.38 better than the analyst estimate of $1.61. Revenue for the quarter came in at $2.28 billion versus the consensus estimate of $2.21 billion.
GUIDANCE:
Biogen sees FY2026 EPS of $15.25-$16.25, versus the consensus of $14.92.
For earnings history and earnings-related data on Biogen (BIIB) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- Live Oak Bancshares, Inc. (LOB) Misses Q3 EPS by 14c
- Oceaneering (OII) Misses Q3 EPS by 9c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
